VEGZELMA DIN 02534185
Status: Marketed
Holder: CELLTRION INC.
Health Canada record
| Active ingredient(s) | BEVACIZUMAB 400 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Intravenous |
|---|
| Schedule | SCHEDULE D; PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | L01FG01 BEVACIZUMAB |
|---|
| Original market date | 01-May-2023 |
|---|
| Current status date | 28-Mar-2024 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Celltrion Healthcare Canada Limited — licence 3-002622, currently licensed, last inspection rating C (2025-11-12).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing BEVACIZUMAB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02522160 | ABEVMY | BIOCON BIOLOGICS CANADA INC | Solution | BEVACIZUMAB 400 MG | Marketed |
| 02522179 | ABEVMY | BIOCON BIOLOGICS CANADA INC | Solution | BEVACIZUMAB 100 MG | Marketed |
| 02270994 | AVASTIN | HOFFMANN-LA ROCHE LIMITED | Solution | BEVACIZUMAB 25 MG | Marketed |
| 02522829 | AYBINTIO | SAMSUNG BIOEPIS CO., LTD | Solution | BEVACIZUMAB 100 MG | Marketed |
| 02522837 | AYBINTIO | SAMSUNG BIOEPIS CO., LTD | Solution | BEVACIZUMAB 400 MG | Marketed |
| 02520729 | BAMBEVI | APOTEX INC | Solution | BEVACIZUMAB 100 MG | Marketed |
| 02520737 | BAMBEVI | APOTEX INC | Solution | BEVACIZUMAB 400 MG | Marketed |
| 02567865 | BEVQOLVA | CURATEQ BIOLOGICS PRIVATE LIMITED | Solution | BEVACIZUMAB 400 MG | Approved |
| 02567830 | BEVQOLVA | CURATEQ BIOLOGICS PRIVATE LIMITED | Solution | BEVACIZUMAB 100 MG | Approved |
| 02470748 | MVASI | AMGEN CANADA INC | Solution | BEVACIZUMAB 25 MG | Marketed |
| 02470756 | MVASI | AMGEN CANADA INC | Solution | BEVACIZUMAB 25 MG | Marketed |
| 02534177 | VEGZELMA | CELLTRION INC. | Solution | BEVACIZUMAB 100 MG | Marketed |
| 02489430 | ZIRABEV | PFIZER CANADA ULC | Solution | BEVACIZUMAB 100 MG | Marketed |
| 02489449 | ZIRABEV | PFIZER CANADA ULC | Solution | BEVACIZUMAB 400 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 32981 | 2024-03-28 | New Drug Submission (NDS) | Administrative - Merger/Buy-out |
| 29820 | 2023-01-03 | New Drug Submission (NDS) | |
Request a quote for VEGZELMA
How to read a Canadian DIN record